Evidence map›Paper›PMID 35157549›Full record

ArticleSubstance use & misuse2022

Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research.

Thomas Patton, Paul Revill, Mark Sculpher, Annick Borquez

Abstract read
In one paragraph

Article in Substance use & misuse, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Analyzing quality of life among people with opioid use disorder from the National Institute on Drug Abuse Data Share initiative: implications for decision making.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Article
  3. Blockchain Applications in the Pharmaceutical Industry.Blockchain in healthcare today · 2024
    Article
  4. Article
  5. Interpol review of forensic management, 2019-2022.Forensic science international. Synergy · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas PattonDivision of Infectious Diseases and Global Public Health, University of California San Diego, California, USA.ORCID 0000-0002-5134-3308
Paul RevillCentre for Health Economics, University of York, York, UK.ORCID 0000-0001-8632-0600
Mark SculpherCentre for Health Economics, University of York, York, UK.ORCID 0000-0003-3746-9913
Annick BorquezDivision of Infectious Diseases and Global Public Health, University of California San Diego, California, USA.ORCID 0000-0002-6033-9837

Funding

Training Program in Substance Use, HIV and Related InfectionsT32DA023356 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Natasha Martin, Steffanie A Strathdee · 2007 to 2026
$7.8M
Real-time prediction of emerging drug use epidemics in the United StatesDP2DA049295 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BORQUEZ, ANNICK · 2019 to 2019
$2.4M
NIDA NIH HHS DP2 DA049295NIDA NIH HHS T32 DA023356
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

EpidemicsOpioid-Related DisordersAnalgesics, OpioidCost-Benefit AnalysisHumansOpioid EpidemicUnited StatesAnalgesics, OpioidEconomic evaluationopioid use disorder

Identifiers

PMID35157549
PMCPMC8969147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.